Azenta Grew 12% by Making Biotech’s Freezers and Sequencers Less Boring

Biotech’s glamorous moments involve Nobel Prizes, dramatic FDA announcements, and founders saying “platform” while standing beside a rendering of a molecule. Azenta’s big moment this week involved something more Massachusetts: a freezer, a sequencing workflow, and a spreadsheet that finally stopped scowling.

On Aug. 4, Burlington-based Azenta reported third-quarter fiscal 2026 results that looked like a useful, slightly untidy step forward. Revenue from continuing operations reached $161 million, up 12% from a year earlier and 11% from the prior quarter. Sample Management Solutions grew 14% year over year to $88 million, while Multiomics rose 10% to $73 million. The company’s results release also raised its full-year organic-revenue outlook from “down 2% to up 1%” to roughly flat to up 1%.

That is not a moonshot. It is better: a report card from the part of the life-sciences economy that has to work before a moonshot can become a trial, a dataset, or a therapy. Azenta stores biological samples, manages repositories, supplies laboratory instruments and consumables, and provides sequencing and gene-synthesis services through brands including GENEWIZ. Its customers are pharmaceutical and biotech companies, hospitals, universities, and research labs—the institutions that produce the scientific breakthroughs while quietly generating an astonishing number of tubes that need to remain cold.

The verdict is a meaningful incremental win, with the little asterisk that keeps the finance department employed. Azenta is growing in the businesses it wants to keep, but the quarter also shows why “turnaround” is a technical condition, not a mood board.

Welcome to the Biotech Supply Chain’s Cold, Square Heart

Sample management sounds like the least cinematic branch of technology until you remember what a modern research organization is actually handling. A laboratory may have blood, tissue, DNA, cell lines, or other specimens collected across studies and locations. Those samples need to be catalogued, tracked, stored at controlled temperatures, retrieved without introducing errors, and connected to the data that describes them.

Azenta sells and operates pieces of that chain. Sample Management Solutions includes repositories, consumables, instruments, and automated stores. Multiomics covers services and tools for reading several layers of biology—such as DNA, RNA, and proteins—to understand what is happening in a sample. The jargon is dense because biology has elected to be a database, a chemistry set, and a municipal permitting office at the same time.

The important point is that this is infrastructure. If a drug company cannot find a sample, trust its chain of custody, or process enough material with consistent results, the expensive part of discovery does not merely slow down. It starts asking existential questions in a conference room.

Azenta’s quarter suggests demand improved across both sides of that business. Sample Management Solutions benefited from higher revenue in repository solutions, consumables, and instruments, although automated stores were weaker. Multiomics growth came primarily from next-generation sequencing and gene synthesis, partially offset by lower Sanger sequencing revenue. That is a very specific mix shift, and specific is good. It means “the market is strong” can be translated into actual machines and services customers bought.

The Turnaround Has Receipts, and Also a Quality-Control Folder

Azenta’s numbers are encouraging, but they are not a clean victory lap. Continuing-operations revenue grew, yet GAAP operating income was still a $4.2 million loss. Adjusted EBITDA was $18.5 million, up modestly from $17.4 million a year ago, while adjusted operating margin fell to 2.9% from 4.7%.

The company specifically cited costs tied to quality remediation and rework activities in Automated Stores. In plain English, some systems needed fixing, correcting, or rebuilding after reality declined to honor the original slide deck. Gross margin also suffered from lower sales volumes in parts of the portfolio and the cost of carrying fixed infrastructure.

This is where the story becomes more interesting than a revenue headline. Automated laboratory storage is a classic physical-AI-adjacent business: software, robotics, refrigeration, inventory logic, sensors, and a room full of valuable material that cannot be treated like a box of spare HDMI cables. The demo can look magical. The hard part is every handoff, every barcode, every recovery procedure, and every sample that arrives at 4:58 p.m. with a label printed by someone who has already mentally left for the weekend.

Azenta’s own disclosure is a reminder that laboratory automation has a weirdness tax. A system can be strategically right and operationally expensive at the same time. Biotech buyers want throughput and traceability, but they also want the machine to behave predictably around irreplaceable material. “Move faster” is not a sufficient acceptance test when the thing being moved is a patient sample.

Goodbye B Medical Systems, Hello Focus

Azenta also completed the sale of B Medical Systems on July 1. The business is now reported as discontinued operations, which makes the continuing-operations picture easier to read. The company received a $35 million secured vendor loan connected to the sale, so this is not a magical disappearance into the accounting clouds, but it is a cleaner strategic perimeter.

That focus matters. Azenta has spent the past year describing a transformation built around its sample-management and multiomics businesses, including cost actions, process redesign, and efforts to improve productivity. The new guidance expects fiscal 2026 revenue from continuing operations between $613 million and $618 million, with organic growth roughly flat to 1%. Multiomics is now expected to range from down 1% to flat, an improvement over the prior “down mid-single-digits” forecast.

No one should confuse that with a victory parade down Route 128. It is the corporate equivalent of getting the basement dry, labelling the circuit breakers, and discovering that the old rowing machine is still somehow plugged into the wrong wall. But strategic focus is often what makes the next improvement possible.

Boston’s Tech Story Is Often the Stuff Behind the Breakthrough

SiliconSnark has covered the region’s more theatrical technical bets, from Mass General’s gene-editing delivery platform to Oak Hill Bio’s rare-disease financing. Those stories are exciting because they put the stakes in the foreground. Azenta is a useful companion piece because it shows the operating layer underneath: the storage, sample movement, sequencing, and measurement that turn a promising experiment into a repeatable program.

It also connects to the region’s broader habit of making technology unusually physical. Massachusetts is funding robotics and AI while writing rules around them; Boston researchers are building reusable delivery systems for medicine. In each case, the interesting work is not only the model, molecule, or policy headline. It is the infrastructure that makes the headline repeatable.

Azenta’s quarter says that infrastructure may be recovering, but it still has to earn trust one instrument, repository, and rework ticket at a time. The company’s 12% growth is a solid signal. The quality costs are the more valuable warning. In biotech, the future is not just invented. It is catalogued, chilled, sequenced, audited, and occasionally retrieved from the wrong drawer.

That makes Azenta a useful incremental win—and a reminder that the Boston tech ecosystem’s most consequential companies may be the ones keeping everyone else’s miracles from thawing.